Corium International is a privately-owned company specializing in the research, development, and production of advanced transdermal drug delivery technologies and products. Leveraging its proprietary delivery technologies along with its development and manufacturing expertise, Corium has created several active and passive transdermal products with improved therapeutic or safety profiles. This self-funded product pipeline covers multiple therapeutic areas and is at various development stages. Additionally, Corium collaborates with several pharmaceutical companies of different sizes on partner-funded products, which are also at different stages of development from manufacturing to research and development.
Founded in 1995, Corium operates in the industries of Biotechnology, Health Care, Manufacturing, and Pharmaceutical. The company recently secured a $235.00M Debt Financing investment on 27 September 2021, with Hercules Capital as the investor.
Corium International's slogan, "Harnessing proprietary technologies to advance transdermal drug delivery for enhanced therapeutic outcomes," reflects its commitment to innovation and improving therapeutic options in the pharmaceutical industry. With its strong focus on research, development, and partnerships, Corium presents significant potential for growth and impact in the healthcare and pharmaceutical sectors.
